93. Primary biliary cholangitis Clinical trials / Disease details

Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05751967 (ClinicalTrials.gov)	February 22, 2023	13/12/2022	Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis	A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis and an Inadequate Response to Ursodeoxycholic Acid	Primary Biliary Cholangitis	Drug: Placebo Combined With Ursodeoxycholic Acid;Drug: Fenofibrate Combined With Ursodeoxycholic Acid	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	75 Years	All	150	Phase 3	China
2	NCT05749822 (ClinicalTrials.gov)	February 17, 2023	29/12/2022	Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis	Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary Cholangitis Who Had an Inadequate Response to Ursodeoxycholic Acid	Primary Biliary Cholangitis	Drug: Fenofibrate 200mg;Drug: Placebo;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	75 Years	All	104	Phase 2/Phase 3	China
3	NCT02965911 (ClinicalTrials.gov)	January 2016	15/11/2016	Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA	A Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCA	Primary Biliary Cirrhosis	Drug: Fenofibrate;Drug: UDCA	Beijing 302 Hospital	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 1/Phase 2	China